Acadia Pharmaceuticals (ACAD) Enterprise Value (2010 - 2026)

Acadia Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$851.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 24.92% year-over-year to -$851.5 million in Q1 2026; TTM through Mar 2026 was -$851.5 million, a 24.92% decrease from a year earlier, with the FY2025 full-year figure at -$819.7 million, down 8.43% from the prior year.
• Enterprise Value eased to -$851.5 million in Q1 2026 per ACAD's latest filing, from -$819.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$345.9 million in Q3 2023 and bottomed at -$851.5 million in Q1 2026.
• The 5-year median for Enterprise Value is -$470.5 million (2024), against an average of -$562.0 million.
• Across the five-year window, Enterprise Value advanced 22.81% in 2022 and tumbled 72.26% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$416.8 million in 2022, then decreased by 5.29% to -$438.9 million in 2023, then sank by 72.26% to -$756.0 million in 2024, then dropped by 8.43% to -$819.7 million in 2025, then slipped by 3.88% to -$851.5 million in 2026.
• Per Business Quant, the three latest ACAD Enterprise Value figures stand at -$851.5 million (Q1 2026), -$819.7 million (Q4 2025), and -$847.0 million (Q3 2025).